Pexastimogene Devacirepvec
Other / unclassified targets CSF2, EGFR
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02977156 | Jan 2017 → Apr 2022 | metastatic neoplasm | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1 | NCT01380600 | Sep 2010 → Oct 2012 | colorectal carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01169584 | Aug 2010 → Mar 2012 | Ewing sarcoma, Wilms tumor, lymphoma, neuroblastoma +1 | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01469611 | Jul 2010 → Oct 2012 | colorectal carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00625456 | Jun 2008 → Apr 2010 | head and neck squamous cell carcinoma, lung cancer, melanoma, renal cell carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00629759 | Jan 2006 → Jul 2007 | liver cancer | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT04849260 | Aug 2021 → May 2022 | metastatic melanoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1/2 | NCT03294083 | Jun 2018 → Feb 2023 | renal cell carcinoma | SillaJen, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03206073 | Dec 2017 → Sep 2020 | colorectal adenocarcinoma, refractory malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03071094 | Jul 2017 → Sep 2020 | hepatocellular carcinoma | Transgene | Terminated | No outcome recorded |
| Phase 1/2 | NCT02630368 | Sep 2015 → May 2023 | breast cancer, soft tissue sarcoma | Institut Bergonié | Unknown | No outcome recorded |
| Phase 1/2 | NCT01394939 | Jan 2012 → Jun 2015 | colorectal carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00429312 | Mar 2007 → Feb 2008 | melanoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02017678 | Jan 2014 → Jan 2015 | ovarian cancer | Andrea McCart | Withdrawn | No outcome recorded |
| Phase 2 | NCT01636284 | Jun 2012 → Jun 2013 | hepatocellular carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01387555 | Oct 2011 → Oct 2013 | hepatocellular carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01329809 | Oct 2011 → Jan 2012 | colorectal carcinoma | Jennerex Biotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT01171651 | May 2009 → Sep 2012 | hepatocellular carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00554372 | Aug 2008 → Dec 2011 | hepatocellular carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02562755 | Oct 2015 → Jul 2020 | hepatocellular carcinoma | SillaJen, Inc. | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pexastimogene devacirepvec | “Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating...” PMID 31413923 ↗ Jun 20195“Pexastimogene Devacirepvec (Pexa-Vec) is one of the new vaccinia oncolytic viruses genetically modified to express GM-CSF.” NCT02977156 ↗ “Pexastimogene Devacirepvec (Pexa Vec)” NCT03071094 ↗ |
| Known as | JX 594 | “Pexa-Vec (JX-594) is a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the expression of transgenes encoding human granulocyte- macrophage...” NCT03206073 ↗13“This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC)” NCT01636284 ↗ |
| Known as | Pexa-Vec, INN pexastimogene devacirepvec | “Pexa-Vec, INN pexastimogene devacirepvec” NCT03206073 ↗ |
| Known as | Pexastimogen devacirepvec | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039547 ↗ |
| Known as | PexaVec | “This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety and tolerability of Pexa-Vec (JX-594), a vaccinia GM-CSF/thymidine kinase-deactivated...” NCT01380600 ↗14“The purpose of this study is to evaluate the safety, tolerability, and efficacy of JX-594 (Pexa-Vec) administered intravenously either alone or in combination with Irinotecan...” NCT01394939 ↗ “BACKGROUND: Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of...” PMID 36754451 ↗ Feb 2023 “The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594...” NCT00629759 ↗ “The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.” NCT00429312 ↗ “Patients will receive either an intravenous infusion or an intratumoral injection of JX-594 (Pexa-Vec) directly into one liver lesions at Day 1.” NCT01329809 ↗ “This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC)” NCT01636284 ↗ “JX-594 (Pexa-Vec) administered by intratumoral injection in patients with metastatic disease to the liver” NCT00625456 ↗ “JX-594 (Pexa-Vec) is an oncolytic and immunotherapeutic vaccinia virus.” PMID 23396206 ↗ Feb 2013 “Pexastimogene Devacirepvec (Pexa Vec)” NCT03071094 ↗ “Pexastimogene Devacirepvec (Pexa Vec)” NCT02562755 ↗ “Combination PexaVec + Ipilimumab” NCT02977156 ↗ |
| Known as | RAC VAC GM-CSF | “JX-594: Recombinant Vaccinia Granulocyte-Macrophage Colony-Stimulating Factor (RAC VAC GM-CSF)” NCT01394939 ↗4“Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)” NCT00625456 ↗ “Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)” NCT01329809 ↗ “Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)” NCT01169584 ↗ “Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)” NCT01380600 ↗ |
| Known as | Recombinant Vaccinia GM-CSF | “Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)” NCT01169584 ↗ |
| Action | Deplete | “designed to selectively replicate in and destroy cancer cells” PMID 18495536 ↗ May 2008 |
| Modality | Other / unclassified | “recombinant vaccinia virus” NCT01169584 ↗ |
| Route | Other | “Intratumoral injection(s) of Recombinant Vaccinia GM-CSF” NCT00429312 ↗ |
| Target | CSF2 | “Granulocyte-macrophage colony-stimulating factor vaccine antigen” CHEMBL3039547 ↗ |
| Target | EGFR | “it is speculated that JX-594 replication targets the EGFR pathway” NCT00429312 ↗ |